SCHEMBL2264060

SCHEMBL2264060

CS(=O)(=O)OC1CCN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 7/20 0.45
CYP3A4 P08684 4/20 0.45
ALOX15 P16050 1/20 0.44
L3MBTL3 Q96JM7 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DPP4 P27487 1/20 0.43
SLC6A9 P48067 1/20 0.43
OPRM1 P35372 3/20 0.41
CHRM2 P08172 2/20 0.41
ADRA2A P08913 2/20 0.41
CHRM1 P11229 2/20 0.41
DRD1 P21728 2/20 0.41
DRD3 P35462 2/20 0.41
SLC6A3 Q01959 2/20 0.41
KCNH2 Q12809 2/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
CHRM3 P20309 1/20 0.41
ADRA1D P25100 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2265275 1.00 CYP2D6 (0.45) CYP2D6CYP3A4ALOX15L3MBTL3L3MBTL1
SCHEMBL5745189 0.92 CYP2D6 (0.44) CYP2D6CYP3A4ALOX15L3MBTL3L3MBTL1
SCHEMBL5745490 0.91 CYP2D6 (0.50) CYP2D6CYP3A4ALOX15L3MBTL3L3MBTL1
SCHEMBL70441 0.88 CYP2D6 (0.46) CYP2D6CYP3A4ALOX15SLC6A9OPRM1
SCHEMBL5746257 0.85 SLC6A9 (0.43) CYP2D6CYP3A4ALOX15L3MBTL3L3MBTL1
SCHEMBL5768225 0.82 SLC6A9 (0.43) CYP2D6CYP3A4ALOX15L3MBTL3L3MBTL1
SCHEMBL2265187 0.82 CYP2D6 (0.52) CYP2D6CYP3A4DPP4SLC6A9OPRM1
SCHEMBL2264882 0.82 CYP2D6 (0.52) CYP2D6CYP3A4DPP4SLC6A9OPRM1
SCHEMBL5514265 0.82 CYP2D6 (0.41) CYP2D6CYP3A4ALOX15DPP4SLC6A9
SCHEMBL24238345 0.81 CYP2D6 (0.40) CYP2D6CYP3A4ALOX15SLC6A9OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1693364-B1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI SANKYO CO LTD (JP) 2015-05-20 EP disclosed
US-7994344-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-08-09 US disclosed
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-7569599-B2 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-08-04 US disclosed
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates DAIICHI SANKYO COMPANY, LIMITED (JP) 2007-05-24 US disclosed
EP-1288198-B1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORP (JP) 2006-12-20 EP disclosed
EP-1693364-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-08-23 EP disclosed
US-6992205-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2006-01-31 US disclosed
US-6864372-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2005-03-08 US disclosed
US-6794519-B2 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2004-09-21 US disclosed
US-20030176711-A1 Process for the production of sulfonic esters KANEKA CORPORATION (JP) 2003-09-18 US disclosed
US-20030176713-A1 Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base KANEKA CORPORATION (JP) 2003-09-18 US disclosed
US-20030162966-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORPORATION (JP) 2003-08-28 US disclosed
EP-1288198-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS KANEKA CORPORATION (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117988-A1 Intermediates for the production of optically active cyclopropylamine derivatives and process for the production of the intermediates RAP1A, RHOA, MGMT CYP2D6 307/4885CYP3A4 59/4885ALOX15 1101/4885
US-20030162966-A1 PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS TST, STS, SELENOI CYP2D6 675/4885CYP3A4 188/4885ALOX15 4247/4885
US-20090240066-A1 INTERMEDIATES FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLOPROPYLAMINE DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE INTERMEDIATES RAP1A, RHOA, MGMT CYP2D6 307/4885CYP3A4 59/4885ALOX15 1101/4885
US-20030176711-A1 Process for the production of sulfonic esters TST, STS, SELENOI CYP2D6 675/4885CYP3A4 188/4885ALOX15 4247/4885
US-20030176713-A1 Reacting an amino alcohol derivative with organic sulfonyl halide in a mixed solvent composed of an aprotic organic solvent and water in presence of a non-water prohibiting inorganic base BRAF, ADH1C, TST CYP2D6 1620/4885CYP3A4 1138/4885ALOX15 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.